1 Coronavirus Vaccine Company to Avoid Like The Plague in May (and Beyond)
Over the past year, several biotechs involved in the hunt for COVID-19 vaccines have been grabbing scores of headlines. And while some of these companies have managed to live up to the hype (in terms of stock performance), others have, thus far, been a flop.
We can safely put Inovio Pharmaceuticals (NASDAQ: INO) in the "flop" category, as the company's shares have thoroughly underperformed over the past 12 months, despite its stratospheric rise in the first half of 2020.
Some might argue that this poor showing represents a buying opportunity, but in my view, Inovio's stock remains unattractive even at current levels. Read on to find out why.
Source Fool.com
